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Abstract: Multiple sclerosis is a frequent neurologic disease, which causes sensory impairment, 
fatigue, cognitive deficits, imbalance, loss of mobility, spasticity, and bladder and bowel dysfunction. 
Several new therapies have been introduced in the past decade, but additional drugs are needed to 
slow disease progression and reduce disability. Natalizumab (NA) is an α4 integrin antagonist, 
effective in decreasing the development of brain lesions in experimental models and in several 
studies of patients with MS. Six randomized controlled trials of NA in MS have been published 
in the last 10 years. Overall, 2,688 relapsing-remitting MS subjects have been enrolled in these 
studies. Hence, there are already sufficient data to draw some conclusions about the effectiveness 
of NA in the treatment of MS, although for definitive considerations it would be reasonable to 
wait for the observational phase IV studies of clinical practice to complete. Moreover, the medical 
community is concerned with the safety of NA, particularly with the risk of developing progressive 
multifocal leukoencephalopathy while on NA therapy. From the analyses of the six cases, it seems 
that the overall risk is around 1/1,000 and could increase with the number of NA infusions.
Keywords: multiple sclerosis, disease-modifying drugs, natalizumab, progressive multifocal 
leukoencephalopathy
Background
Multiple sclerosis (MS) is a leading cause of neurologic disability in young and 
middle-aged patients. The impact of the disease on daily living can be highly disabling 
because the pathological process may affect many functional systems. Patient suffer 
from a variety of neurological symptoms as fatigue, spasticity, bladder, bowel and sexual 
dysfunction, sensory loss, ataxia, or cognitive failure.1,2 But above all, people with MS 
experience psychologic distress and social troubles, which could negatively impact their 
quality of life (QoL) if combined.3,4 One of the main causes of stress is the unpredictable 
and bizarre course of the disease, which affects patients and caregivers alike.
In the last 20 years, the introduction of the disease-modifying drugs (DMDs) 
such as interferon-β (IFNβ) and glatiramer actetate (GA) in relapsing-remitting MS 
(RRMS) and more recently in people with clinically isolated syndromes (CIS) has 
aroused broadly hopeful expectations, mainly focused on their efficacy in slowing 
down the progression of disease and reducing frequency and severity of relapse.5–8 
Unfortunately, IFNβ and GA are only partially effective and most patients with MS 
have breakthrough disease activity despite therapy with these medications.5–8
Other medication or therapeutic strategies have been tried in patients with MS. 
Mitoxantrone (MIT) is the only immunosuppressive drug approved for the treatment 
of worsening forms of RRMS and for progressive-relapsing MS (PRMS) or ClinicoEconomics and Outcomes Research 2009:1 46
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secondary-progressive MS (SPMS), but its potential cardiac 
toxicity must be taken into account.9,10 To avoid or minimize 
this serious adverse event, induction therapy with MIT 
followed by an immunomodulating agent was proposed. 
A short course of MIT followed by IFNβ or GA was found 
to be safe and effective, with an early and sustained decrease 
in magnetic resonance imaging (MRI) disease activity.11,12
A combination of the two classes of recognized first-line 
treatment, a IFNβ and GA, is currently under evaluation in 
a large phase III trial.13 None of the combination studies 
performed with IFNβ to date have pointed out unequivocal 
evidence of benefit, including combinations with statins and 
azathioprine.14
In addition, new drugs have been developed. Among 
them, natalizumab (NA) is an interesting therapy in patients 
with breakthrough disease, especially for those in whom 
DMDs were ineffective or not well tolerated.
In this review, we highlight the clinical efficacy and safety 
profile of NA as well as the impact of MS on patients’ QoL.
Introduction
Natalizumab (NA; Tysabri® Biogen Idec, Cambridge, MA, 
USA and Elan Pharmaceuticals, Gainesville, GA, USA) is a 
recombinant humanized monoclonal antibody, derived from 
a murine monoclonal antibody, targeted against the glycopro-
tein α4 integrin, also called a very late antigen 4 (VLA-4). 
This molecule is expressed on the surface of all circulating 
leukocytes such as lymphocytes and monocytes and has the 
function to mediate the cell adhesion and transendothelial 
migration.15 Adhesion molecules are involved in inflam-
matory demyelination as they enhance systemic immune 
responses into the target tissue.16 Cytokines may play a role 
in upregulating the expressions of these molecules.
In MS, circulating leukocytes enter the central nervous 
system (CNS) and produce inflammation and myelin damage. 
Prevention of leukocyte infiltration may be obtained by an 
antibody against VLA-4.
First efficacy evidence of antibodies against α4 integrin 
in prevention of leukocyte infiltration was observed in 
experimental autoimmune encephalomyelitis (EAE), an 
inflammatory condition of the CNS used as animal model of 
MS.17 Subsequently, Kent and colleagues demonstrated that 
the blockage of VLA-4 suppressed clinical and pathological 
features of EAE in the guinea pig.18
Placebo-controlled studies in humans
The study of the clinical use of NA in MS began with a 
small, short-term, placebo-controlled study. Patients were 
treated twice with NA, 3 mg/kg at weeks 0 and 4. Follow up 
lasted for 24 months. The treated group showed significantly 
fewer new active nuclear MRI (NMR) lesions and fewer new 
enhancing lesions than the placebo group.19 Several years 
later, in a broader controlled double-blind trial on 213 patients 
with RRMS or relapsing SPMS, NA was administered at 
two different doses (3 or 6 mg/kg) every 28 days for six 
months. Patients under active treatment showed marked 
reduction in the mean number of new gadolinium-enhancing 
lesions (0.7 per patient in the group given 3 mg, 1.1 in the 
group given 6 mg) in comparison with the placebo group 
(9.6 per patient). Additionally, both NA-treated groups 
reported fewer relapses and an improvement in general well 
being. Most frequent adverse events were headache, urinary 
tract infection, and muscle weakness.20
A randomized trial with NA was also carried out in 
patients with acute MS relapses.21 A single dose of NA (1 or 
3 mg/kg) or placebo were administered just after the onset 
of an exacerbation in 180 patients. There was no difference 
in Expanded Disability Status Scale (EDSS) score variation 
over time between treatment and placebo groups, but both 
treated groups showed a significant decrease in gadolinium-
enhancing lesion volume when compared with placebo. 
Overall, NA was well tolerated; the most frequent side 
effects were headache, pharyngitis, dizziness, and nausea. 
The percentages of patients with side effects were similar 
between the two different dose-treated groups.
In the GLANCE trial, 110 patients, who were treated with 
GA for at least one year and who had experienced at least one 
exacerbation, were randomized to receive either GA plus NA 
or GA plus placebo. The primary end-point was the rate of 
new active lesion on MRI. Patients treated with GA plus NA 
reported a 74% reduction in new gadolinium-enhancing T1 
lesions and a 62% reduction in new or enlarging T2 lesions. 
No significant adverse events were observed in patients 
treated with combination therapy.22
Following the GLANCE trial, two phase III, randomized, 
double-blind, placebo-controlled trials, AFFIRM and 
SENTINEL, were executed. In the AFFIRM study,23 Tysabri® 
(NA); administered to 627 patients with RRMS at a dose of 
300 mg every four weeks for more than two years, produced 
a reduction of sustained progression of disability by 42%. 
Moreover, the rate of clinical relapse and the accumulation 
of new or enlarging hyperintense NMR lesions decreased by 
68% and by 83%, respectively. The treated group reported 
more frequently than placebo fatigue and allergic reaction; 
serious hypersensitivity reactions occurred in eight patients. 
Two patients in the NA group died during the study. The former ClinicoEconomics and Outcomes Research 2009:1 47
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had already a diagnosis of malignant melanoma and had 
already noted a new skin lesion when the first dose of NA was 
administered. On the whole, five doses of NA were injected 
before the patients received a confirmed diagnosis. The latter 
died of alcohol intoxication after having received 25 doses of 
NA. Nevertheless, the authors concluded that NA monotherapy 
had an excellent safety and tolerability profile in addition to the 
significant reduction of disability progression and occurrence 
of clinical relapse.
Unfortunately, the enthusiasm for the safety of NA was 
dramatically dampened with the results of the SENTINEL 
study.24 In this study there were two cases of progressive 
multifocal leukoencephalopathy (PML), one of which was 
fatal. Despite these adverse events, the clinical and NMR 
outcomes had not been unfavorable. NA was given to 1,171 
RRMS patients at a dose of 300 mg, in combination with 
IFNβ-1a. These patients had had at least one exacerba-
tion despite the IFNβ therapy, during the 12-month period 
before the randomization. Combination therapy determined 
a 24% reduction of relative risk of sustained disability 
progression and a lower annualized rate of relapse over a 
two-year period in comparison with IFNβ-1a alone. Beside, 
combination therapy produced fewer new or enlarging lesions 
on T2-weighted NMR.
Subsequently, the incidence and clinical effects of 
antibodies that developed over two years of NA treatment 
among patients included in the AFFIRM and SENTINEL 
studies was reported. In the AFFIRM study, antibodies were 
found in 57 of 625 (9%) patients, of whom 20 (3%) were 
transiently positive and 37 (6%) were persistently positive. 
Patients with persistent positive antibody showed a significant 
loss of clinical efficacy as assessed by disability progression, 
relapse rate, and MRI in comparison with antibody-negative 
patients. Similar results were obtained in SENTINEL 
except with regard to disability progression and lack of 
significant differences among persistently antibody-positive 
and antibody-negative subjects.25 The same trouble had been 
present during IFNβ therapy, in which the presence of neutral-
izing antibodies (Nab) reduced or abolished bioavailability 
in a relevant percentage of patients.26
These findings suggested the opportunity to investigate 
NA antibody during immunomodulating treatment in those 
patients with suboptimal clinical response.
NA in gastroenterology
NA had been used in people with Crohn’s disease (CD). 
The pathogenesis of CD involves persistent recruitment of 
leukocytes into gut tissue, with resultant inflammation.
Several studies have suggested that NA may be effective 
for the treatment of active CD.27–29 Two controlled trials were 
conducted to test NA as induction and maintenance therapy in 
CD. The first trial, known as ENACT-1, included 905 patients, 
of whom 724 were randomly assigned to receive 300 mg 
of NA. In the second trial (ENACT-2) which included 339 
patients who were responders to NA, 168 were randomly reas-
signed to receive NA. In ENACT-1, two patients treated with 
NA died, the former from asphyxiation due to an occupational 
accident, the latter from complication of surgery due to a 
severe exacerbation of CD. In ENACT-2, one patient died 
from PML associated with the John Cunningham virus; one 
patient developed a basal-cell carcinoma of the skin; influ-
enza and influenza-like disease occurred more frequently in 
the NA group than in placebo group and finally, there was 
one report each of varicella pneumonia and cytomegalovirus 
hepatitis, both in the NA-treated group.30
The dilemma of safety
At this point there was a pause for reflection and it was decided 
to retest the profile of safety and tolerability. Thus, in February 
2005, NA was withdrawn from the market. All NA-treated 
patients (n = 3,417) were re-examined. Of 44 patients who 
were identified with clinical findings of possible PML, 43 were 
successively ruled out. Data on cerebrospinal fluid testing and 
follow-up MRI of the remaining patients were not available. 
The authors concluded that the risk of PML in patients 
treated with NA is roughly 1 in 1,000, but the risk associ-
ated with longer treatment remained to be determined.31
Following these findings and based on the recommendation 
of an advisory committee, NA was approved by the US Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMEA) in people with intensely active RRMS, 
who were not responding to IFNβ therapy or in patients who 
experienced faster disability progression, even if not previously 
treated with IFNβ. Nevertheless, the question of the safety of 
NA is anything but clarified. At the FDA hearing for market re-
approval, several cases of unusual infections in patients treated 
with NA were reported32 (Table 1). The role of NA in deter-
mining these infections, if in whole or in part, is not yet clear. 
This raises doubt whether NA may compromise cell-mediated 
immunity. And moreover, it enhances the prudence to initiate 
NA treatment in combination with other immunosuppressant. 
Further research in larger cohorts and for a longer time should 
clarify the above issues. For these purposes, a large-scale post-
registration study (the TYGRIS study) is ongoing.
In the course of 2008 and 2009, information on new 
cases of PML became available. To date (July 2009), a 10th ClinicoEconomics and Outcomes Research 2009:1 48
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confirmed case of PML has occurred among patients with 
MS who had used NA. However, it appears that when PML 
is detected and treated early, outcome is generally improved. 
In conclusion, it is important that patients taking NA and 
their doctors become more vigilant in monitoring for any 
occurrence of new, unusual symptoms that might indicate 
PML.33 Typical symptoms associated with PML progress over 
days to weeks and can include progressive weakness on one 
side of the body, disturbances of vision, cognitive deficits, and 
personality changes. Because of the risk of PML, Tysabri® 
is available in the US only through the TOUCH (Tysabri® 
Outreach Unified Commitment to Health) prescribing 
program. TOUCH is a restricted distribution program focused 
on safety and minimizing the risk of PML.34
Risk-benefit and cost-effectiveness
Several reports have sought to quantify the risk and benefits 
of NA in RRMS using quality-adjusted life years (QALY) 
as a metric, which gives a single index score for each state 
of health (full health = 1, death = 0).
The most pressing question was to verify whether the 
beneficial health effects of NA on reducing relapses and 
slowing down disease progression overcame the negative 
effects of PML on QALY. Dorsey observed that, even after 
increasing the current estimated risk of PML by 10, the net 
health effects of NA are clearly positive.35 Over the first 
two years of NA therapy, the negative health effects from 
PML were small (loss of 0.001 QALY) in comparison 
with the positive effects on relapse and disability gained 
(0.033 QALY).
Very recently, long-term health changes in NA-treated 
patients were compared with the health profiles modeled for 
a natural history cohort and with IFNβ-1a-treated patients. 
The natural history cohort accumulated 8.70 QALY over the 
20-year time horizon. NA produced a further 0.80 QALY 
gained for a total of 9.50 QALY, while IFNβ-1a resulted in 
an additional 0.42 QALY for a total of 9.12 QALY gained36 
(Figure 1). On these grounds, a more than sevenfold increase 
in risk of PML is necessary to diminish NA health gain below 
that of IFNβ-1a.36
The cost-effectiveness of NA was estimated in comparison 
with IFNβ, GA, and supportive care. The incremental 
cost-effectiveness ratios (ICERs), calculated for the base 
case, was found to be £2,300 per QALY for NA compared 
with IFNβ, £2,000 per QALY for NA versus GA, £8,200 per 
QALY for NA versus supportive care. The authors deduced 
that NA is likely to be a cost-effective therapy for patients 
with highly active RRMS.37 In the same way, Kobelt and 
colleagues explained that treatment with NA was less 
expensive and more effective than treatment with other 
available current DMDs. Taking into account only health 
care costs, the cost per QALY gained with NA was found to 
be  38,145.38
Recent evidence
Post-marketing observational reports have clearly demon-
strated the relative safety and tolerability of NA. In a recent 
county-based surveillance program on 909 patients, the most 
common adverse events were allergic reactions and usually 
mild infections. Drug inefficacy, adverse events and detection 
of anti-natalizumab antibody were the most frequent causes 
of NA therapy suspension, while no other cases of death or 
major side effects were described.39
In the past two years, there have been published other 
reports, some of which highlighting beneficial effects of NA. 
Balcer and colleagues examined the effects of NA on visual 
Table 1 Opportunistic infections in the natalizumab-treated 
patients
Infections No. of cases
viral meningitis and encephalitis 2 (one fatal)
Acute cytomegalovirus 2
Pulmonary aspergillosis 2
Cryptosporidial gastroenteritis 1
Pneumocystis carinii pnemonia 1
varicella pneumonia 1
Mycobacterium avium complex pneumonia 1
Burkholderia cepacia pneumonia 1
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Figure 1 Long-term health changes.
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function in the two randomized clinical trials, AFFIRM and 
SENTINEL, by means of low-contrast letter acuity. The risk 
of clinical significant visual loss at the lowest contrast level 
was reduced in the NA-treated groups by 35% in AFFIRM 
and by 28% in SENTINEL, while mean changes in vision 
scores worsened in non-NA groups.40
Recently, Havrdova and colleagues reported on post-hoc 
analyses of data from the AFFIRM study to determine the 
effects of NA in comparison with placebo on the proportion 
of patients who were free of disease activity over two years: 
383 (64%) of 596 patients taking NA and 117 (39%) of 301 
taking placebo were free of clinical disease activity, and 
342 (58.5%) of 593 and 42 (14%) of 296 of placebo group 
were free of radiological disease activity.41
Despite the favorable clinical effects of NA, there are also 
a few concerns the overall effects of NA. The occurrence 
of early relapses after the first dose of NA in active MS 
patients was reported by Centonze and colleagues in seven of 
35 patients who had had at least two clinical relapses during a 
12-month therapy with other immunomodulatory drugs. The 
exacerbations were mild and achieved their peak of severity 
within 18–30 hours after NA administration. However, all 
patients recovered spontaneously or after a short course of 
intravenous high dose steroid injection.42
Vellinga and colleagues described a post-withdrawal 
rebound increase in T2 lesional activity in NA-treated 
MS patients.43 At variance with this study, O’Connor and 
colleagues demonstrated that there was not evidence of 
rebound increase in MRI.44 In Vellinga and colleagues’ 
study, NA had been discontinued when cases of PML 
were observed and patients underwent safety MRI 
before the reintroduction on NA. Some of them showed 
a considerable number of new T2 lesions, developed in 
the 15-month interval between the suspension and the 
reintroduction of NA.43
Stüve and colleagues evaluated immune activity in the 
blood and spinal fluid, relapse rates, disease progression 
and MRI scans 14 months after the cessation of NA admin-
istration. These authors found that at 14 months, most were 
stable, with no new clinical disease activity, MRI activity or 
immune activity.45 Similarly, Schiess and Calabresi suggested 
that stopping Tysabri® after increasing the number of drug 
administrations was not associated with rebound syndrome, 
whereas stopping the drug after only a few doses could cause 
disease worsening.46
Little is known on the use of NA in pediatric MS. Huppke 
and colleagues reported the safety and the effectiveness of 
NA in three pediatric RRMS patients who had failed to 
immunomodulatory therapy. NA was given at a dosage of 3 to 
5 mg/kg for 15 months; no other exacerbation occurred and 
QoL significantly improved.47
Effects of NA on health-related 
quality of life
In the last 10 years, several authors detected the relationship 
between DMDs and health-related QoL (HRQol). This field 
of research has assumed a broad importance given the high 
expectations from treatment with DMDs and its relative 
frequent side effects which could substantially influence 
the HRQoL of patients and caregivers. Furthermore, the 
intrinsic nature of the disease and the known differences of 
what is more important for patients and physicians led many 
neurologists to include the use of scales assessing the personal 
perception of the disease in their clinical practice.48 These 
scales measure QoL and reflect the patients’ personal point 
of view of the “illness”. Neurologists should also incorporate 
QoL measurement instruments such as the Short Form-36 
Health Survey (SF-36), Multiple Sclerosis Quality of Life-54 
Instrument (MSQOL-54), Sickness Impact profile with 
the Expanded Disability Status Scale,49 Multiple Sclerosis 
Functional Composite Measure,50 and neuropsychological 
tests for cognitive impairment.51
There are very few reports of the impact of NA on HRQoL 
in patients with MS. The largest data were collected from 
2.113 patients enrolled in both AFFIRM and SENTINEL 
studies. HRQoL was investigated trough the SF-36 and a 
single-item subject global assessment visual analog scale. NA 
significantly improved SF-36 physical component summary 
(PCS) and mental component summary (MCS) scores at 
week 104 in AFFIRM. PCS changes resulted significantly 
improved by week 24 and in all successive examinations. 
Higher change scores on the PCS and MCS were obtained 
at all post-baseline time points for patients treated with NA, 
while placebo-treated patients had worsening scores at five of 
the six time points. In SENTINEL, patients treated with NA 
plus IFNβ showed higher PCS scores at weeks 52 and 104. 
NA-treated patients in both studies were more likely to 
experience clinically important improvement and less likely 
to experience clinically important deterioration on the 
SF-36 PCS.52
Therefore, it seems NA therapy could determine a 
beneficial effect on both psychological and physical 
profiles. The improvement of QoL undoubtedly would lead 
to coping better with the challenges of a chronic disease 
as MS. Nevertheless, this point must be interpreted with 
caution, considering the previous analyses on the effects ClinicoEconomics and Outcomes Research 2009:1 50
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of IFNβ therapies on MS patients’ QoL, which provided 
conflicting evidence. These studies have taught us that QoL 
can be affected by several demographic, social, and clinical 
variables such as age, education, employment, disability, 
depression, and adverse treatment events.
Similar to what was observed in MS patients, HRQoL of 
CD patients benefited from NA treatment. The Inflammatory 
Bowel Disease Questionnaire and the SF-36 scores of 
patients who responded to NA induction remained stable, 
but worsened in those patients randomized to receive 
placebo.53
Conclusion
The introduction of Tysabri® on the market for the treatment 
of people with MS was firstly associated with the enthusiasm 
of patients and clinicians for a drug at least eight-fold 
more effective than previous DMDs. These first years of 
NA use in clinical practice raised the question of safety. 
PML is considered a serious problem associated with NA 
therapy. We do not know if there is a cumulative dose of NA 
before PML is provoked. It seems from the analyses of the 
10 available cases that the overall risk is around 1 in 1,000 
(there are more than 50,000 people under treatment with NA 
worldwide) which could increase with the number of NA 
infusions. The risk of cardiotoxicity and leukemia increases 
with higher doses of mitoxantrone. In the same way, the risk of 
definitive amenorrhea or cystitis increases with higher doses of 
cyclophoshamide, which is sometimes used as rescue therapy. 
These considerations tend to limit the use of NA in the case 
of MS. However, we think that the risk/benefit ratio favors 
treating patients with NA. Moreover, the evidence of PML in 
patients treated with other biologic drugs such as infliximab, 
etanercept, and rituximab have taught clinicians to recognize 
and diagnose earlier PML and manage it properly. The use of 
plasma exchange and the proper use of steroids are reported as 
effective and safe. It should be emphasized that the introduction 
on the market of this new drug and the possible future medi-
cations for treating MS patients has deeply changed the role 
and the attitude of treating physicians in clinical practice who 
should consider safety first and efficacy second.
We think that the possible skepticism and safety 
concerns raised by the “new era” of treating MS could be 
considered as reassuring for both clinicians and patients, if 
neurologists change their habits and properly approach the 
new challenge.
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